Abstract 232P
Background
Anal carcinoma’s incidence is rising, and although it is rare, it has a poor survival if metastatic (1). Circulating tumor DNA (ctDNA) could be a less invasive technique to evaluate molecular alteration (2). We aimed to describe patients with anal carcinoma (AC) and MA to estimate their impact on overall survival (OS), and the possibility to receive an early access treatment (targeted or not).
Methods
We centralized liquid biopsies and tissue samples between two French centers. We collected data on demographics, tumor type, previous treatments, HPV status and clinical outcomes. We assessed MA based on ESCAT classification, pan-tumoral, due to the lack of ESCAT classification dedicated to AC. Patients and tumors characteristics were assessed at baseline.
Results
A total of 68 patients were included in the analysis. Our patients were mostly women (57%) aged of 63 years (57;72). Squamous cell carcinomas were the most frequent histology type (61), 22 patients (NA = 39) had p16-positive tumors and 2 patients (NA = 39) were infected with HIV. 26 patients (39%) were metastatic at diagnosis. A total of 39.7% (N = 27) patients showed targetable MA according to ESCAT. Most frequents targetable MA founded were PI3KCA (12), PTEN (5), ATM (5), ERBB2 (2), ERBB3 (1), EGFR (2), ATR (1), FGFR2 (1), POLE (1), and TMB high (19%, N=13). OS among patients with targetable MA did not differ from patients without targetable MA, or in patients who received or not an early access treatment.
Conclusions
Our study found a significant number of patients presenting targetable MA, with no differences in OS between those two groups. It can be explained by the scarcity of accessible studies for these patients during our follow-up. Those findings could emphasize the need for new studies among these patients given the frequency of targetable MA and the development of new-targeted therapy.
Legal entity responsible for the study
Institut Bergonié, Bordeaux, France.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.